A5052264374- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Cancer Cells and Metastasis
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Pancreatic and Hepatic Oncology Research
- Melanoma and MAPK Pathways
- Hematopoietic Stem Cell Transplantation
- Lung Cancer Treatments and Mutations
- Protein Degradation and Inhibitors
- Cancer Genomics and Diagnostics
- Cancer Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Esophageal Cancer Research and Treatment
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- vaccines and immunoinformatics approaches
- Head and Neck Cancer Studies
- HER2/EGFR in Cancer Research
- Acute Lymphoblastic Leukemia research
- Radiomics and Machine Learning in Medical Imaging
- T-cell and B-cell Immunology
- Acute Myeloid Leukemia Research
- Click Chemistry and Applications
- Nanoplatforms for cancer theranostics
University of Pennsylvania
2015-2024
Parker Institute for Cancer Immunotherapy
2019-2024
Cancer Research And Biostatistics
1998-2023
Hospital of the University of Pennsylvania
1997-2019
University at Buffalo, State University of New York
2018
Philadelphia University
2005-2015
University of Pennsylvania Health System
2012-2015
Pennsylvania Hospital
2015
Cancer Research Center
1993-2013
Penn Center for AIDS Research
2012-2013
Abstract The dynamics of cancer immunosurveillance remain incompletely understood, hampering efforts to develop immunotherapy cancer. We evaluated the evolving in vivo immune response a spontaneous tumor genetically defined mouse model pancreatic ductal adenocarcinoma from inception preinvasive disease invasive observed prominent leukocytic infiltration even around lowest grade lesions, but immunosuppressive cells, including tumor-associated macrophages, myeloid-derived suppressor cells...
Liver fibrosis, the response to chronic liver injury, results from activation of mesenchymal cells fibrogenic myofibroblasts. We have recently shown that two key myofibroblast precursor populations, hepatic stellate and portal fibroblasts, undergo in culture increasing substrate stiffness. therefore hypothesized alterations stiffness precede fibrosis vivo as well. To test this hypothesis, we induced rats by twice weekly injections carbon tetrachloride (CCl 4 ) then killed animals at various...
PURPOSE In an attempt to understand some of the complex issues related participation cancer patients in phase I trials, and perceptions toward these we conducted a pilot survey study 30 who had given informed consent participate trial at our institution. Concurrently, oncologists identified by surveyed as responsible for their care were well. PATIENTS AND METHODS Twenty-seven consecutive agreed completed survey. Patients before they received any investigational agents. Eighteen participated...
We conducted a pilot clinical trial testing personalized vaccine generated by autologous dendritic cells (DCs) pulsed with oxidized whole-tumor cell lysate (OCDC), which was injected intranodally in platinum-treated, immunotherapy-naïve, recurrent ovarian cancer patients. OCDC administered alone (cohort 1, n = 5), combination bevacizumab 2, 10), or plus low-dose intravenous cyclophosphamide 3, 10) until disease progression exhaustion. A total of 392 doses were without serious adverse events....
To determine the clinical importance of immunophenotypes in adult acute lymphoblastic leukemia (ALL), we prospectively studied 76 patients with this condition. Before treatment, lymphoblasts were tested for reactivity monoclonal antibodies to B-cell, T-cell, and myeloid (My) antigens. Unexpectedly, antigens (MCS-2 or MY9) identified 25 (33 percent), usually conjunction B-cell T-cell Among My+ patients, 15 (60 percent) expressed (B+T-y+); all 6 had rearranged immunoglobulin genes. Five (20...
CD25 monoclonal antibody therapy rapidly and durably depletes T regs in cancer patients through a mechanism consistent with reprogramming.
Patients with oligometastatic non-small cell lung cancer (NSCLC) may benefit from locally ablative therapy (LAT) such as surgery or stereotactic radiotherapy. Prior studies were conducted before the advent of immunotherapy, and a strong biological rationale for use immunotherapy exists in minimal residual disease state.To evaluate whether addition pembrolizumab after LAT improves outcomes patients NSCLC.This single-arm phase 2 trial was performed February 1, 2015, through September 30, 2017,...
Graft-versus-host disease (GVHD) is a major barrier to successful allogeneic hematopoietic stem-cell transplantation (HSCT). The chemokine receptor CCR5 appears play role in alloreactivity. We tested whether blockade would be safe and limit GVHD humans.We the vitro effect of antagonist maraviroc on lymphocyte function chemotaxis. then enrolled 38 high-risk patients single-group phase 1 2 study reduced-intensity HSCT that combined with standard prophylaxis.Maraviroc inhibited internalization...
Chemotherapy combined with immunotherapy has improved the treatment of certain solid tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma (PDAC). We conducted a randomized phase 2 trial evaluating efficacy nivolumab (nivo; anti-PD-1) and/or sotigalimab (sotiga; CD40 agonistic antibody) gemcitabine/nab-paclitaxel (chemotherapy) in patients first-line metastatic PDAC ( NCT03214250 ). In 105 analyzed efficacy, primary endpoint 1-year overall survival (OS) was met...
Abstract Purpose: Whole tumor lysates are promising antigen sources for dendritic cell (DC) therapy as they contain many relevant immunogenic epitopes to help prevent escape. Two common methods of lysate preparations freeze-thaw processing and UVB irradiation induce necrosis apoptosis, respectively. Hypochlorous acid (HOCl) oxidation is a new method inducing primary enhancing the immunogenicity cells. Experimental Design: We compared ability DCs engulf three different preparations, produce...
PURPOSE Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved as maintenance therapy for patients with advanced pancreatic cancer (PC) and germline BRCA1 or BRCA2 pathogenic variant (PV). This investigator-initiated, single-arm phase II study assessed the role of PARPi rucaparib in PC somatic PV BRCA1, BRCA2, PALB2. PATIENTS AND METHODS Eligible had PC; (g) (s) PVs PALB2, received at least 16 weeks platinum-based chemotherapy without evidence platinum resistance....
CD40 activation is a novel clinical opportunity for cancer immunotherapy. Despite numerous active trials with agonistic monoclonal antibodies (mAb), biological effects and treatment-related modulation of the tumor microenvironment (TME) remain poorly understood.
Abstract BACKGROUND Breast magnetic resonance imaging (MRI) is a developing technique for the evaluation of patients with primary breast carcinoma. The authors assessed impact preoperative MRI on surgical management. METHODS current study was retrospective review 267 tumors who had studies prior to undergoing definitive surgery. RESULTS Two hundred sixty‐seven invasive carcinoma and complete clinical, radiologic, pathologic data available were identified formed basis this analysis. overall...
PURPOSE: Recent studies have suggested that the sentinel lymph node (SLN) biopsy is an accurate alternative staging procedure for women with breast cancer. The goal of this study was to identify a subset cancer patients in whom metastatic disease confined only SLN. MATERIALS AND METHODS: From two institutions, we recruited 222 SLN biopsy. A performed each patient, followed by axillary dissection 182 patients. Histologic and immunohistochemical cytokeratin stains were used on all SLNs....
No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Jan 2003An Interval Longer than 12 Weeks Between the Diagnosis Muscle Invasion and Cystectomy is Associated with Worse Outcome in Bladder Carcinoma RICARDO F. SÁNCHEZ-ORTIZ, WILLIAM C. HUANG, ROSEMARIE MICK, KEITH N. VAN ARSDALEN, ALAN J. WEIN, S. BRUCE MALKOWICZ SÁNCHEZ-ORTIZRICARDO SÁNCHEZ-ORTIZ , HUANGWILLIAM HUANG MICKROSEMARIE MICK ARSDALENKEITH ARSDALEN WEINALAN WEIN MALKOWICZS. View All Author...
Overexpression of HER-2/neu (c-erbB2) is associated with increased risk recurrent disease in ductal carcinoma situ (DCIS) and a poorer prognosis node-positive breast cancer. We therefore examined the early immunotherapeutic targeting DCIS. Before surgical resection, HER-2/neu(pos) DCIS patients (n = 13) received 4 weekly vaccinations dendritic cells pulsed HLA class I II peptides. The vaccine were activated vitro IFN-gamma bacterial lipopolysaccharide to become highly polarized DC1-type that...